Full-Time

Principal Scientist

Machine Learning

Confirmed live in the last 24 hours

ArsenalBio

ArsenalBio

201-500 employees

Develops programmable cell therapies for cancer

Biotechnology
Healthcare

Compensation Overview

$200.1k - $245.1kAnnually

Senior, Expert

San Bruno, CA, USA

This is a hybrid position based in the South San Francisco office.

Category
Applied Machine Learning
Deep Learning
AI & Machine Learning
Required Skills
Python
Machine Learning
Linux/Unix

You match the following ArsenalBio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Ph.D. in Computer Science, Electrical Engineering, Statistics, Biomedical Engineering, Bioinformatics, or a related field, with 7+ years of industry experience
  • OR Master’s degree in one of the above fields, with 12+ years of industry experience
  • Proven track record of developing novel deep-learning models with applications to biological questions
  • Familiarity with single-cell sequencing data
  • Ability to work collaboratively and communicate effectively in an interdisciplinary environment
  • Strong software engineering skills, proficiency in Python, and familiarity with state-of-the-art libraries for deep learning model training
  • Experience working in Linux-based cloud computing environments.
Responsibilities
  • Design and implement novel ML architectures that leverage massive single-cell datasets to assist with drug discovery and development
  • Work closely with experimental scientists to guide our data processing and generation strategies to maximize model performance for specific applications
  • Publish and present at academic conferences
  • Train and mentor a growing team of ML scientists and engineers.

ArsenalBio focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is currently in the clinical stage, concentrating on research and development to bring these therapies to market. Unlike many competitors, ArsenalBio emphasizes a diverse team of experts from various scientific and clinical backgrounds, which aids in their goal of creating effective cancer treatments. Their ultimate aim is to provide innovative therapies that can significantly improve outcomes for patients suffering from solid tumor cancers.

Company Size

201-500

Company Stage

Series C

Total Funding

$612.8M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $325 million funding boosts ArsenalBio's clinical development capabilities.
  • Partnerships with Thermo Fisher enhance ArsenalBio's manufacturing and technological capabilities.
  • Growing demand for personalized medicine aligns with ArsenalBio's programmable cell therapy focus.

What critics are saying

  • Emerging competition from companies like Allogene Therapeutics in CAR T-cell therapies.
  • High manufacturing costs may affect ArsenalBio's pricing and market competitiveness.
  • Regulatory scrutiny on gene-editing technologies could delay therapy approvals.

What makes ArsenalBio unique

  • ArsenalBio integrates CRISPR, synthetic biology, and machine learning for advanced cell therapies.
  • Their focus on solid tumors sets them apart in the CAR T-cell therapy space.
  • ArsenalBio's CITE technology enhances T-cell targeting and tumor microenvironment overcoming.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-1%

2 year growth

16%
Arsenal Bio
Jan 6th, 2025
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

Bakersfield.com
Sep 16th, 2024
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.

BioPharma Reporter
Sep 5th, 2024
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies

ArsenalBio bags $325 million to develop crispr-engineered cell therapies.

Arsenal Bio
Sep 4th, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development • Arsenal Bio

Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]

CityBiz
Sep 4th, 2024
T. Rowe Price Joins $325 Million Financing for ArsenalBio

T. Rowe Price joins $325 million financing for ArsenalBio.